Capricor (CAPR) Q3 2026 Earnings Call Transcript
Capricor (CAPR) Q3 2026 Earnings Call Transcript(摘要待生成)
CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retail’s Attention Remains Firmly Fixed On Nov. 22 FDA Decision For Deramiocel - Yahoo Finance
CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retail’s Attention Remains Firmly Fixed On Nov. 22 FDA Decision For Deramiocel - Yahoo Finance(摘要待生成)
CAPR Dec 2026 2.000 put (CAPR261204P00002000) Stock Price, News, Quote & History - Yahoo! Finance Canada
CAPR Dec 2026 2.000 put (CAPR261204P00002000) Stock Price, News, Quote & History Yahoo! Finance Canada
Capricor Stock: The FDA's Objections Change My June Buy To A Sell (NASDAQ:CAPR) - Seeking Alpha
Capricor Stock: The FDA's Objections Change My June Buy To A Sell (NASDAQ:CAPR) Seeking Alpha
Capricor Therapeutics shares rise as FDA decision nears
Capricor Therapeutics shares rise as FDA decision nears(摘要待生成)
Capricor Therapeutics, 8-K (2.02, 9.01): reported results of operations
Capricor reported third-quarter 2026 results, said its Deramiocel DMD application remains under FDA review with a November 22, 2026 target date, highlighted 76% slower upper-limb decline after placebo patients switched to treatment, and reported approximately $199 million in cash and securities.
CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring
CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring Yahoo Finance